These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3476862)

  • 1. [Behavior of CA 19-9 in benign pathology of the gastrointestinal tract. Preliminary data].
    Magri GC; Maculotti L; Vigorelli R
    Minerva Chir; 1987 May; 42(10):901-3. PubMed ID: 3476862
    [No Abstract]   [Full Text] [Related]  

  • 2. [CA 19-9 in benign diseases of the gastrointestinal tract].
    Klapdor R
    Dtsch Med Wochenschr; 1986 Jun; 111(26):1039. PubMed ID: 3459644
    [No Abstract]   [Full Text] [Related]  

  • 3. Carcinoembryonic antigen in benign and malignant diseases of the digestive tract.
    Zamcheck N; Moore TL; Dhar P; Kupchik HZ; Sorokin JJ
    Natl Cancer Inst Monogr; 1972 Dec; 35():433-9. PubMed ID: 4659055
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of biliary tract obstruction and cholangitis on serum CA 19-9 levels].
    Okaga M; Karasawa H; Kobayashi T; Satsukime N; Miki R
    Nihon Shokakibyo Gakkai Zasshi; 1985 May; 82(5):1418. PubMed ID: 3861895
    [No Abstract]   [Full Text] [Related]  

  • 5. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
    Klapdor R; Greten H
    Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
    [No Abstract]   [Full Text] [Related]  

  • 6. [Evaluation of CA 19-9 radioimmunoassay].
    Toya D; Takemori Y; Kidani H; Yoneshima M; Hattori N; Sawabu N
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):509-14. PubMed ID: 6584087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with the tumor marker Ca 19-9 in an unselected group of more than 300 tumor patients.
    Souchon R; Koppenhagen K; Souchon MF; Matthes M; Boese-Landgraf J; Fitzner R; Baer U
    Cancer Detect Prev; 1985; 8(1-2):101-9. PubMed ID: 3864534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The behavior of blood CA 15.3 in patients with non-tumor pathologies. Preliminary results].
    Ruibal A; Guarga A; Encabo G; Gris JM
    Med Clin (Barc); 1986 Feb; 86(6):262. PubMed ID: 3458017
    [No Abstract]   [Full Text] [Related]  

  • 9. [Carbohydrate antigen (CA-19-9) in the blood serum of patients with benign and malignant liver diseases].
    Ametov AS; Kasatkin IuN; Mit'kov VV; Gur'eva IV
    Med Radiol (Mosk); 1985 Mar; 30(3):39-41. PubMed ID: 3856723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of a cancer antigen CA 125 associated with ovarian cancer. (IV) Serum CA 125 levels through normal menstrual cycle and in benign diseases].
    Suzuki M; Sekiguchi I; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1985 Mar; 33(3):285-8. PubMed ID: 3859676
    [No Abstract]   [Full Text] [Related]  

  • 11. [Assay of CA 19-9 in cancer of the pancreas: preliminary results].
    Gosselin P; Besson P; Demaille MC; Sulman C
    LARC Med; 1984; 4(6):383. PubMed ID: 6590940
    [No Abstract]   [Full Text] [Related]  

  • 12. [CA 19-9 enzyme immunoassay].
    Ota H; Odani H; Watanabe H; Satomura Y; Takemori Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
    Gan No Rinsho; 1986 Aug; 32(9):993-7. PubMed ID: 3528560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological diagnosis and prognosis of digestive tract cancer: some clinical considerations.
    Zamcheck N
    Ann Immunol (Paris); 1973 Nov; 124(4):635-40. PubMed ID: 4792503
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evaluation of a new tumor marker (CA 50) in epithelial neoplasms. Preliminary study].
    Tozzoli R; Risaliti A; Masiero M; Bruno G
    Minerva Chir; 1987 Nov; 42(21):1785-8. PubMed ID: 3480454
    [No Abstract]   [Full Text] [Related]  

  • 15. [Serum level of the tumor marker CA 125 in ovarian pathology].
    Bagni B; Pansini FS; Feggi LM; Prandini N; Mollica G
    Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CEA in normal individuals and in clinical disorders.
    Booth SN; King J; Leonard J; Dykes PW
    Ann Immunol (Paris); 1973 Nov; 124(4):631-2. PubMed ID: 4792502
    [No Abstract]   [Full Text] [Related]  

  • 17. [CA 19-9, a new tumor marker].
    Akai S
    Rinsho Byori; 1983 Dec; 31(12):1300-2. PubMed ID: 6587136
    [No Abstract]   [Full Text] [Related]  

  • 18. [Preliminary study on detecting the CA 125 value in endometrial washings].
    Chen DX; Schwartz PE
    Zhonghua Fu Chan Ke Za Zhi; 1987 Sep; 22(5):288-90, 312. PubMed ID: 3481694
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical significance of serum CA 19-9 in patients with gastric and colorectal carcinoma and immunohistochemical visualization of CA 19-9 in tumor tissues.
    Sekikawa K
    Fukushima J Med Sci; 1985 Jun; 31(1):29-42. PubMed ID: 3866740
    [No Abstract]   [Full Text] [Related]  

  • 20. [Preoperative determination of carcinoembryonic antigen and gastrointestinal antigen in neoplastic colorectal pathology. Case contributions].
    Ramella A; Bussone R; Sanlorenzo M; Natta F; Caldarola B; Schirripa C; Giani R; Pecchio F; Rocca N
    Minerva Chir; 1987 Jun; 42(12):1037-43. PubMed ID: 3476864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.